NB patients are classified into low-, intermediate-, and high-risk categories according to the presence of clinical and biological parameters (such as age at diagnosis, MYCN amplification, recurrent segmental chromosomal aberrations, diploid DNA index, and poorly differentiated or undifferentiated histology) for therapeutic stratification [3]. The gene discussed is MYCN; the disease is neuroblastoma.